Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ph Gabriel Steg

Showing results (1-10 of 229) with videos related to

Pageof 23
Sort By:
Journal of the American College of Cardiology|December 19, 2003
Circadian variations in outcome of primary percutaneous coronary interventionPh Gabriel Steg, Philippe Garot
European Heart Journal|November 4, 2021
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethylPh Gabriel Steg, Deepak L Bhatt
Archives of Cardiovascular Diseases|March 16, 2010
Statins in the elderly: what evidence of their benefit in prevention?Ph Gabriel Steg, Claire-Marie Tissot
European Heart Journal. Acute Cardiovascular Care|October 15, 2015
Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stentsPh Gabriel Steg, Deepak L Bhatt
Heart (British Cardiac Society)|July 6, 2013
2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient managementPh Gabriel Steg, Stefan K James, Bernard J Gersh
Progress in Cardiovascular Diseases|April 11, 2025
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozinRam D Bhatt, Bertram Pitt, Ph Gabriel Steg, et al.
European Journal of Preventive Cardiology|January 3, 2024
Omega-3 fatty acids for cardiovascular event loweringGurleen Kaur, R Preston Mason, Ph Gabriel Steg, et al.
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
Journal of the American College of Cardiology|October 5, 2019
Reply: Ischemic Event Reduction and TriglyceridesDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
Pageof 23

Showing results (1-10 of 229) with videos related to

Sort By:
Pageof 23
Journal of the American College of Cardiology|December 19, 2003
Circadian variations in outcome of primary percutaneous coronary interventionPh Gabriel Steg, Philippe Garot
European Heart Journal|November 4, 2021
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethylPh Gabriel Steg, Deepak L Bhatt
Archives of Cardiovascular Diseases|March 16, 2010
Statins in the elderly: what evidence of their benefit in prevention?Ph Gabriel Steg, Claire-Marie Tissot
European Heart Journal. Acute Cardiovascular Care|October 15, 2015
Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stentsPh Gabriel Steg, Deepak L Bhatt
Heart (British Cardiac Society)|July 6, 2013
2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient managementPh Gabriel Steg, Stefan K James, Bernard J Gersh
Progress in Cardiovascular Diseases|April 11, 2025
Incremental benefits of combined inhibition of SGLT1 and SGLT2 with sotagliflozinRam D Bhatt, Bertram Pitt, Ph Gabriel Steg, et al.
European Journal of Preventive Cardiology|January 3, 2024
Omega-3 fatty acids for cardiovascular event loweringGurleen Kaur, R Preston Mason, Ph Gabriel Steg, et al.
European Heart Journal|September 2, 2009
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trialKim Fox, Ian Ford, Ph Gabriel Steg, et al.
The American Journal of Medicine|February 19, 2018
The ReplyPaul R Kalra, Nicola Greenlaw, Ian Ford, et al.
Journal of the American College of Cardiology|October 5, 2019
Reply: Ischemic Event Reduction and TriglyceridesDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
Pageof 23